Highlights Race Oncology Limited

Equities

RAC

AU000000RAC3

Delayed Australian S.E. Other stock markets 10:03:13 2024-05-23 pm EDT			5-day change	1st Jan Change
1.46 ^AUD	+0.34%		-5.81%	+73.81%

Mar. 26	Race Oncology Obtains Certificate of Analysis for RC220; Shares Up Almost 6%	MT
Mar. 18	Race Oncology Limited(ASX:RAC) dropped from S&P/ASX All Ordinaries Index	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Race Oncology Obtains Certificate of Analysis for RC220; Shares Up Almost 6%	Mar. 25	MT
Race Oncology Widens Loss in Fiscal H1	Feb. 27	MT
Race Oncology Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 27	CI
Race Oncology Initiates Toxicology, Safety Pharmacology Studies of Chemotherapy Drug	23-10-05	MT
Race Oncology Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Race Oncology Secures More R&D Tax Rebate for Fiscal Year 2022; Shares Rise 4%	23-07-12	MT
Race Executes Agreement with Ardena for GMP Manufacturing of RC220	23-07-12	CI
Race Oncology Signs Manufacturing Deal for Intravenous Formulation; Shares Fall 4%	23-07-11	MT
Race Oncology Limited Executes Global License Agreement with City of Hope to Access FTO IP	23-07-10	CI
Race Oncology Secures License Deal for Cancer Research Intellectual Property	23-07-10	MT
Race Oncology Limited Announces Board Changes	23-06-28	CI
Tranche Update on Race Oncology Limited's Equity Buyback Plan announced on June 9, 2022.	23-06-22	CI
Race Oncology Limited's Equity Buyback announced on June 9, 2022, has closed with 634,881 shares, representing 0.40% for AUD 1.28 million.	23-06-21	CI
Race Oncology Receives AU$1.5 Million R&D Tax Rebate	23-03-27	MT
Race Oncology Ties Up with US University for Oncology Drug Study	23-03-02	MT
Race Oncology Limited Initiates New Collaboration to Understand Zantrene Cardioprotection Mechanism	23-03-01	CI
Race Oncology Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-27	CI
Race Oncology Secures Human Ethics Approval for Zantrene Trial	23-02-01	MT
Race Oncology Limited Receives Human Ethics Approval for Observational Cardioprotection Breast Cancer Trial	23-01-31	CI
Race Oncology Advances Preclinical and Clinical Studies for Protein Inhibitor	22-12-26	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Race Oncology Limited

Equities

RAC

AU000000RAC3

Highlights

Filters